Henlius and Accord's Zercepac (trastuzumab- biosimilar) Receive the EMA Approval for HER2-Positive Breast Cancer and Gastric Cancer
Shots:
- The approval is based on comparative quality studies- clinical studies including preclinical data and resulted in bio-similarity- comparable efficacy and safety of Zercepac (HLX02) vs Herceptin
- Zercepac is developed under NMPA and EMA biosimilar guidelines and has been evaluated with the reference trastuzumab including comparative quality studies- preclinical studies- a P-I clinical study and a global multi-center P-III clinical study
- Zercepac is a novel China-mAb approved in the EU for the treatment of HER2+ early breast cancer- HER2+ metastatic breast cancer- and HER2+ metastatic gastric cancer with an expected launch in China in 2020 while its manufacturing site has received EU GMP certificates
Ref: Henlius | Image: Behance
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com